Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEP-F1 + GLA-SE vaccine safety and immunogenicity study in adults in a leprosy-endemic region
RBR-88jm8ykPhase 2Not yet recruiting
- Sponsor
- Bio-Manguinhos
- Start
- Jan 2022
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of liposomal fenofibrate and GLA-SE adjuvant in leprosy (HD) and borderline tuberculoid leprosy (BT) (6 arms), sponsored by Bio-Manguinhos. Primary endpoints: Safety, Tolerability and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
liposomal fenofibrateGLA-SE adjuvant
03
Conditions
leprosy (HD)borderline tuberculoid leprosy (BT)
Beyond the preview
Go deeper on RBR-88jm8yk.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-88jm8yk.